Management of Kaposi's sarcoma in resource-limited settings in the era of HAART

Simple item page
dc.contributor.authorLynen L.
dc.contributor.authorZolfo M.
dc.contributor.authorHuyst V.
dc.contributor.authorLouis F.
dc.contributor.authorBarnardt P.
dc.contributor.authorde Velde A.
dc.contributor.authorDe Schacht C.
dc.contributor.authorColebunders R.
dc.date.accessioned2011-05-15T16:15:17Z
dc.date.available2011-05-15T16:15:17Z
dc.date.issued2005
dc.description.abstractThe introduction of highly active antiretroviral therapy (HAART) has changed the natural history of AIDS-associated Kaposi's sarcoma (KS). Although the use of HAART remains limited in low-resource settings, there are global initiatives to make these drugs available to several millions of HIV-infected persons. While there are multiple reports of KS regression during HAART with or without chemotherapy, there is little documentation on KS management in resource-limited settings. In this paper we review current KS treatments available worldwide and discuss the implications of the increased access to antiretrovirals for KS treatment strategies in resource-limited settings.
dc.description.versionReview
dc.identifier.citationAIDS Reviews
dc.identifier.citation7
dc.identifier.citation1
dc.identifier.issn11396121
dc.identifier.urihttp://hdl.handle.net/10019.1/13271
dc.subjectalitretinoin
dc.subjectalpha interferon
dc.subjectantiretrovirus agent
dc.subjectbleomycin
dc.subjectcorticosteroid
dc.subjectdaunorubicin
dc.subjectdidanosine
dc.subjectdoxorubicin
dc.subjectetoposide
dc.subjectmetronidazole
dc.subjectpaclitaxel
dc.subjectproteinase inhibitor
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectstavudine
dc.subjectvinblastine
dc.subjectVinca alkaloid
dc.subjectvincristine
dc.subjectzidovudine
dc.subjectacquired immune deficiency syndrome
dc.subjectanaphylaxis
dc.subjectanemia
dc.subjectappetite disorder
dc.subjectareflexia
dc.subjectasthenia
dc.subjectbone marrow suppression
dc.subjectchill
dc.subjectclinical feature
dc.subjectconfusion
dc.subjectconstipation
dc.subjectdeveloping country
dc.subjectdisease exacerbation
dc.subjectdrug cost
dc.subjectdrug dose regimen
dc.subjectdrug hypersensitivity
dc.subjectextravasation
dc.subjectfever
dc.subjecthighly active antiretroviral therapy
dc.subjecthuman
dc.subjectHuman immunodeficiency virus infection
dc.subjecthyporeflexia
dc.subjecthypotension
dc.subjectileus
dc.subjectinjection pain
dc.subjectKaposi sarcoma
dc.subjectliver dysfunction
dc.subjectlung fibrosis
dc.subjectneurologic disease
dc.subjectneurotoxicity
dc.subjectneutropenia
dc.subjectperipheral neuropathy
dc.subjectRaynaud phenomenon
dc.subjectreview
dc.subjectrigor
dc.subjectsensorimotor neuropathy
dc.subjectskin irritation
dc.subjectskin manifestation
dc.subjectthrombocytopenia
dc.subjecttissue necrosis
dc.subjecttreatment indication
dc.subjectwheezing
dc.subjectAntiretroviral Therapy, Highly Active
dc.subjectDeveloping Countries
dc.subjectHIV Infections
dc.subjectHumans
dc.subjectSarcoma, Kaposi
dc.titleManagement of Kaposi's sarcoma in resource-limited settings in the era of HAART
dc.typeReview
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications